Nov 25 (Reuters) – The U.S. government is expected this week to announce negotiated prices for 15 of the highest-cost prescription drugs under its Medicare health plan, a potential signal of the Trump administration’s commitment to bring down healthcare costs.
Sign up here.
Analysts said they will be looking at how the prices compare to Medicare’s recent net prices after accounting for confidential rebates and discounts. They will also be comparing them to prices negotiated by other high-income countries, a concept President Donald Trump has fought for, sometimes referred to as most-favored-nation pricing.
Medicare covers more than 67 million people age 65 and over and those with disabilities.
US negotiated Medicare prices for 15 more drugs to test cost savings promise
